A Customized Efficient Deep Learning Model for the Diagnosis of Acute Leukemia Cells Based on Lymphocyte and Monocyte Images

Data Availability Statement: The data related to this article are publicly available on the GitHub platform under the title Ansari acute leukemia images.Copyright © 2023 by the authors. The production of blood cells is affected by leukemia, a type of bone marrow cancer or blood cancer. Deoxyribonucleic acid (DNA) is related to immature cells, particularly white cells, and is damaged in various ways in this disease. When a radiologist is involved in diagnosing acute leukemia cells, the diagnosis is time consuming and needs to provide better accuracy. For this purpose, many types of research have been conducted for the automatic diagnosis of acute leukemia. However, these studies have low detection speed and accuracy. Machine learning and artificial intelligence techniques are now playing an essential role in medical sciences, particularly in detecting and classifying leukemic cells. These methods assist doctors in detecting diseases earlier, reducing their workload and the possibility of errors. This research aims to design a deep learning model with a customized architecture for detecting acute leukemia using images of lymphocytes and monocytes. This study presents a novel dataset containing images of Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML). The new dataset has been created with the assistance of various experts to help the scientific community in its efforts to incorporate machine learning techniques into medical research. Increasing the scale of the dataset is achieved with a Generative Adversarial Network (GAN). The proposed CNN model based on the Tversky loss function includes six convolution layers, four dense layers, and a Softmax activation function for the classification of acute leukemia images. The proposed model achieved a 99% accuracy rate in diagnosing acute leukemia types, including ALL and AML. Compared to previous research, the proposed network provides a promising performance in terms of speed and accuracy; and based on the results, the proposed model can be used to assist doctors and specialists in practical applications.This research received no external funding

cGAL, a temperature-robust GAL4–UAS system for Caenorhabditis elegans

The GAL4–UAS system is a powerful tool for manipulating gene expression, but its application in Caenorhabditis elegans has not been described. Here we systematically optimize the system's three main components to develop a temperature-optimized GAL4–UAS system (cGAL) that robustly controls gene expression in C. elegans from 15 to 25 °C. We demonstrate this system's utility in transcriptional reporter analysis, site-of-action experiments and exogenous transgene expression; and we provide a basic driver and effector toolkit

Suppression of charged particle production at large transverse momentum in central Pb-Pb collisions at sNN=2.76\sqrt{s_{\rm NN}} = 2.76 TeV

Inclusive transverse momentum spectra of primary charged particles in Pb-Pb collisions at $\sqrt{s_{_{\rm NN}}}$ = 2.76 TeV have been measured by the ALICE Collaboration at the LHC. The data are presented for central and peripheral collisions, corresponding to 0-5% and 70-80% of the hadronic Pb-Pb cross section. The measured charged particle spectra in $|\eta|<0.8$ and $0.3 < p_T < 20$ GeV/$c$ are compared to the expectation in pp collisions at the same $\sqrt{s_{\rm NN}}$, scaled by the number of underlying nucleon-nucleon collisions. The comparison is expressed in terms of the nuclear modification factor $R_{\rm AA}$. The result indicates only weak medium effects ($R_{\rm AA} \approx$ 0.7) in peripheral collisions. In central collisions, $R_{\rm AA}$ reaches a minimum of about 0.14 at $p_{\rm T}=6$-7GeV/$c$ and increases significantly at larger $p_{\rm T}$. The measured suppression of high-$p_{\rm T}$ particles is stronger than that observed at lower collision energies, indicating that a very dense medium is formed in central Pb-Pb collisions at the LHC.Comment: 15 pages, 5 captioned figures, 3 tables, authors from page 10, published version, figures at http://aliceinfo.cern.ch/ArtSubmission/node/98

Two-pion Bose-Einstein correlations in central Pb-Pb collisions at sNN\sqrt{s_{\rm NN}} = 2.76 TeV

The first measurement of two-pion Bose-Einstein correlations in central Pb-Pb collisions at $\sqrt{s_{\rm NN}} = 2.76$ TeV at the Large Hadron Collider is presented. We observe a growing trend with energy now not only for the longitudinal and the outward but also for the sideward pion source radius. The pion homogeneity volume and the decoupling time are significantly larger than those measured at RHIC.Comment: 17 pages, 5 captioned figures, 1 table, authors from page 12, published version, figures at http://aliceinfo.cern.ch/ArtSubmission/node/388

Single-cell analysis tools for drug discovery and development

The genetic, functional or compositional heterogeneity of healthy and diseased tissues presents major challenges in drug discovery and development. Such heterogeneity hinders the design of accurate disease models and can confound the interpretation of biomarker levels and of patient responses to specific therapies. The complex nature of virtually all tissues has motivated the development of tools for single-cell genomic, transcriptomic and multiplex proteomic analyses. Here, we review these tools and assess their advantages and limitations. Emerging applications of single cell analysis tools in drug discovery and development, particularly in the field of oncology, are discussed

Current issues in medically assisted reproduction and genetics in Europe: research, clinical practice, ethics, legal issues and policy. European Society of Human Genetics and European Society of Human Reproduction and Embryology.

In March 2005, a group of experts from the European Society of Human Genetics and European Society of Human Reproduction and Embryology met to discuss the interface between genetics and assisted reproductive technology (ART), and published an extended background paper, recommendations and two Editorials. Seven years later, in March 2012, a follow-up interdisciplinary workshop was held, involving representatives of both professional societies, including experts from the European Union Eurogentest2 Coordination Action Project. The main goal of this meeting was to discuss developments at the interface between clinical genetics and ARTs. As more genetic causes of reproductive failure are now recognised and an increasing number of patients undergo testing of their genome before conception, either in regular health care or in the context of direct-to-consumer testing, the need for genetic counselling and preimplantation genetic diagnosis (PGD) may increase. Preimplantation genetic screening (PGS) thus far does not have evidence from randomised clinical trials to substantiate that the technique is both effective and efficient. Whole-genome sequencing may create greater challenges both in the technological and interpretational domains, and requires further reflection about the ethics of genetic testing in ART and PGD/PGS. Diagnostic laboratories should be reporting their results according to internationally accepted accreditation standards (International Standards Organisation - ISO 15189). Further studies are needed in order to address issues related to the impact of ART on epigenetic reprogramming of the early embryo. The legal landscape regarding assisted reproduction is evolving but still remains very heterogeneous and often contradictory. The lack of legal harmonisation and uneven access to infertility treatment and PGD/PGS fosters considerable cross-border reproductive care in Europe and beyond. The aim of this paper is to complement previous publications and provide an update of selected topics that have evolved since 2005

Patient-derived xenograft (PDX) models in basic and translational breast cancer research

Patient-derived xenograft (PDX) models of a growing spectrum of cancers are rapidly supplanting long-established traditional cell lines as preferred models for conducting basic and translational preclinical research. In breast cancer, to complement the now curated collection of approximately 45 long-established human breast cancer cell lines, a newly formed consortium of academic laboratories, currently from Europe, Australia, and North America, herein summarizes data on over 500 stably transplantable PDX models representing all three clinical subtypes of breast cancer (ER+, HER2+, and "Triple-negative" (TNBC)). Many of these models are well-characterized with respect to genomic, transcriptomic, and proteomic features, metastatic behavior, and treatment response to a variety of standard-of-care and experimental therapeutics. These stably transplantable PDX lines are generally available for dissemination to laboratories conducting translational research, and contact information for each collection is provided. This review summarizes current experiences related to PDX generation across participating groups, efforts to develop data standards for annotation and dissemination of patient clinical information that does not compromise patient privacy, efforts to develop complementary data standards for annotation of PDX characteristics and biology, and progress toward "credentialing" of PDX models as surrogates to represent individual patients for use in preclinical and co-clinical translational research. In addition, this review highlights important unresolved questions, as well as current limitations, that have hampered more efficient generation of PDX lines and more rapid adoption of PDX use in translational breast cancer research

Acute Leukemia Diagnosis Based on Images of Lymphocytes and Monocytes Using Type-II Fuzzy Deep Network

Data Availability Statement: The data related to this article are publicly available on the GitHub platform under the title Ansari acute leukemia images.Copyright © 2023 by the authors. A cancer diagnosis is one of the most difficult medical challenges. Leukemia is a type of cancer that affects the bone marrow and/or blood and accounts for approximately 8% of all cancers. Understanding the epidemiology and trends of leukemia is critical for planning. Specialists diagnose leukemia using morphological analysis, but there is a possibility of error in diagnosis. Since leukemia is so difficult to diagnose, intelligent methods of diagnosis are required. The primary goal of this study is to develop a novel method for extracting features hierarchically and accurately, in order to diagnose various types of acute leukemia. This method distinguishes between acute leukemia types, namely Acute Lymphocytic Leukemia (ALL) and Acute Myeloid Leukemia (AML), by distinguishing lymphocytes from monocytes. The images used in this study are obtained from the Shahid Ghazi Tabatabai Oncology Center in Tabriz. A type-II fuzzy deep network is designed for this purpose. The proposed model has an accuracy of 98.8% and an F1-score of 98.9%, respectively. The results show that the proposed method has a high diagnostic performance. Furthermore, the proposed method has the ability to generalize more satisfactorily and has a stronger learning performance than other methods.This research received no external funding